Literature DB >> 32287066

Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Christel Protiere1,2, Marion Fiorentino1,2, Abdourahmane Sow1,2, Marie Préau3, Marion Mora1,2, Lisa Fressard2,4,5, Laurence Meyer6, Jean-Daniel Lelièvre7,8,9, Olivier Lambotte10,11,12,13, Bruno Spire1,2, Marie Suzan-Monti1,2.   

Abstract

: Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32287066     DOI: 10.1097/QAD.0000000000002530

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  1 in total

1.  Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Authors:  Karen L Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R Mollan; Laney Henley; Angela M Stover; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-16       Impact factor: 1.723

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.